DIVI S LABORATORIES LTD vs JUBILANT PHARMOVA LTD

A side-by-side comparison of DIVI S LABORATORIES LTD (DIVISLAB) and JUBILANT PHARMOVA LTD (JUBLPHARMA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, DIVI S LABORATORIES LTD leads DIVISLAB vs JUBLPHARMA on 10 of 14 metrics (1 tied). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

74.93
P/E ratio
40.87
10.72
P/B ratio
2.19
0.44%
Dividend yield
0.52%
₹96.73
EPS
₹25.02

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

16.50%
Return on equity
6.55%
22.00%
Return on capital
9.00%
33.00%
EBITDA margin
15.00%
24.32%
Net margin
4.81%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.78%
Revenue CAGR (3Y)
9.64%
12.10%
Profit CAGR (3Y)

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.92L Cr
Market cap
₹16,228 Cr
₹10,560 Cr
Revenue
₹8,280 Cr
₹2,568 Cr
Net profit
₹398 Cr
0.00
Debt / equity
0.51
DIVI S LABORATORIES LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
  • ["Stock is trading at 10.8 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
JUBILANT PHARMOVA LTD
  • + ["Company has been maintaining a healthy dividend payout of 43.9%", "Company's working capital requirements have reduced from 28.6 days to 13.4 days"]
  • ["The company has delivered a poor sales growth of 6.31% over past five years.", "Company has a low return on equity of 5.80% over last 3 years.", "Company might be capitalizing the interest cost", "Promoter holding has decreased over last 3 years: -3.01%"]
DIVI S LABORATORIES LTD full analysis JUBILANT PHARMOVA LTD full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.